Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial


Por: Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, Korozan M, de las Penas R, Majem M, Chella A, Griesinger F, Bournakis E, Sadjadian P, Kotsakis A, Chinet T, Syrigos K, Correale P, Gallou C, Jamet J, Vetsika E, Kosmatopoulos K, Georgoulias V, Vx 001 201 Trial Team

Publicada: 1 may 2020 Ahead of Print: 1 mar 2020
Resumen:
Background The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT572 CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). Methods A randomised, double blind, phase 2b trial, in HLA-A*201-positive patients with metastatic, TERT-expressing NSCLC, who did not progress after first-line platinum-based chemotherapy were randomised to receive either Vx-001 or placebo. The primary endpoint of the trial was OS. Results Two hundred and twenty-one patients were randomised and 190 (101 and 89 patients in the placebo and the Vx-001 arm, respectively) were analysed for efficacy. There was not treatment-related toxicity >grade 2. The study did not meet its primary endpoint (median OS 11.3 and 14.3 months for the placebo and the Vx-001, respectively; p = 0.86) whereas the median Time to Treatment Failure (TTF) was 3.5 and 3.6 months, respectively. Disease control for >6months was observed in 30 (33.7%) and 26 (25.7%) patients treated with Vx-001 and placebo, respectively. There was no documented objective CR or PR. Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004). Conclusion Vx-001 could induce specific CD8(+) immune response but failed to meet its primary endpoint. Subsequent studies have to be focused on the identification and treatment of subgroups of patients able to mount an effective immunological response to Vx-001.

Filiaciones:
Gridelli C:
 SG Moscati Hosp, Avellino, Italy

Ciuleanu T:
 Oncol I Chircuta, Cluz Napoca, Romania

Domine M:
 Fdn Jimenez Diaz, Madrid, Spain

Szczesna A:
 Mazowieckie Ctr, Otwock, Poland

Bover I:
 Son Llatzer Hosp, Palma De Mallorca, Spain

Cobo M:
 Hosp Reg Univ Malaga, Inst Invest Biomed IBIMA, Malaga, Spain

Kentepozidis N:
 251 Gen Airforce Hosp, Athens, Greece

Zarogoulidis K:
 Papanikolaou Gen Hosp, Exohi, Greece

Kalofonos C:
 Univ Hosp Patras, Rion, Greece

Kazarnowisz A:
 Oddzial Onkol Pododdziatem, Olsztyn, Poland

Korozan M:
 Hosp Dutkiewicza SAC, Gdansk, Poland

de las Penas R:
 Hosp Prov Castellon, Castellon de La Plana, Spain

Majem M:
 Hosp Santa Creui St Pau, Barcelona, Spain

Chella A:
 AOU Pisa Hosp, Pisa, Italy

Griesinger F:
 Pius Hosp, Oldenburg, Germany

Bournakis E:
 Univ Hosp Aretaieion, Athens, Greece

Sadjadian P:
 Johannes Wesling Klinikum, Minden, Germany

Kotsakis A:
 Univ Gen Hosp Larissa, Dpt Med Oncol, Larisa, Greece

Chinet T:
 Hop Ambroise Pare, Boulogne, France

Syrigos K:
 Gen Hosp Thorac Dis Sotiria, Athens, Greece

Correale P:
 Univ Hosp Siena, Siena, Italy

Gallou C:
 Vaxon Biotech, Paris, France

Jamet J:
 Vaxon Biotech, Paris, France

Vetsika E:
 Univ Gen Hosp Heraklion, Iraklion, Crete, Greece

Kosmatopoulos K:
 Vaxon Biotech, Paris, France

Georgoulias V:
 Univ Gen Hosp Heraklion, Iraklion, Crete, Greece
ISSN: 00070920





BRITISH JOURNAL OF CANCER
Editorial
Nature Publishing Group, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 122 Número: 10
Páginas: 1461-1466
WOS Id: 000521527700004
ID de PubMed: 32210365

MÉTRICAS